In 2023, Sino Biopharm's R&D investment reached 4.4 billion yuan, accounting for 16.8% of total revenue, with 6 innovative drugs and biosimilars approved. The number of innovative products surged from 2 in 2015 to 11 in 2023.

As the innovation landscape continues to expand, innovative products have become a significant driver of the company's revenue growth. In 2023, the company's income from innovative products reached 9.89 billion yuan, increasing by 13.3% year-on-year. The proportion of innovation-driven income to total revenue rapidly rose from 11% in 2015 to 38% in 2023.

In the next three years, Sino Biopharm will enter a period of intensive harvest under a comprehensive innovation strategy. Only in 2024,Bemarituzumab(TQB2450), ALK inhibitor I-fenati (TQB3139), ROS1 inhibitor Anai Ketini (TQB3101), Liraglutide and other innovative products are expected to be approved for marketing.

In China, the 3rd ranked pharmaceutical company is Fosun Pharmaceutical, which ranks 17th globally.

In 2023, Fosun Pharmaceutical's total R&D investment amounted to RMB 5.937 billion, representing a year-on-year increase of 0.88%; of which R&D expenses were RMB 4.346 billion, marking a year-on-year increase of 1.02%. The R&D investment in pharmaceuticals business was RMB 5.172 billion, up by 1.47% year-on-year.

Fosun Pharmaceutical has over 70 innovative drugs and biosimilar projects under research and development (calculated by indication). In the future, the company will focus on four core technology platforms: small molecules, antibodies/ADC, RNA, and cell therapy, while actively exploring frontier technologies such as cancer vaccines and AI-driven drug discovery.

CSPC Pharmaceutical Group Limited has ranked among the top 25 global pipeline scales for the second consecutive year, placing 24th, and is also the 4th largest pharmaceutical company in China.

R&D expenses in 2023 reached RMB 4.83 billion (recorded in the income statement), increasing by 21.2% year-on-year, accounting for approximately 18.8% of the revenue from the finished drug business.

Currently, CSPC Pharmaceutical Group Limited has over 60 key drugs in the clinical or application stage, of which 7 have submitted marketing applications, and 18 are in the registration clinical stage.

In 2023, CSPC Pharmaceutical Group Limited entered into an exclusive licensing agreement with Corbus Pharmaceuticals, Inc., granting the latter the development and commercialization rights for the antibody-drug conjugate SYS6002 in the United States, the European Union, the United Kingdom, and other regions.

CSPC Pharmaceutical Group Limited Receives $7.5 Million as the First Payment, and is Entitled to Receive up to $130 Million in Potential Development and Regulatory Milestone Payments as well as up to $555 Million in Potential Sales Milestone Payments.

Source: Pharma Investment Tribe

Recommended Reading